WCLC 2026 Plenary Studies Clinical Evidence Review Report

This report frames the IASLC World Conference on Lung Cancer (WCLC 2026), held 12–15 September 2026 in Seoul, Republic of Korea, around four plenary themes (PL01–PL04) and a dedicated artificial-intelligence-in-oncology track. It provides an integrated clinical-evidence review of nine plenary-anchored studies spanning screening, access and survivorship; small cell lung cancer (SCLC) post-induction strategy and relapsed-SCLC antibody–drug conjugates (ADCs); first-line PD-L1-high and EGFR-driven non-small cell lung cancer (NSCLC); and a mixed EGFR exon 20 insertion / ROS1 / HER2 group. The report is organized around evidence maturity, so each study's clinical question, design, population, treatment versus comparator, endpoints, disclosed findings, and unresolved questions are assessed on the same footing. It clearly separates established readouts (ADAURA's long-term follow-up, PAPILLON's PFS benefit with a pending OS analysis) from interim or topline-only disclosures (REZILIENT3, DESTINY-Lung04), and treats the negative EVOKE-03/KEYNOTE-D46 result — and its subsequent programme discontinuation by Merck and Gilead — as an important interpretive anchor rather than a footnote. It also carefully distinguishes commonly conflated assets and definitions, including Tam-Peli/YL201 as a B7-H3 ADC (not a TROP2 ADC and not risvutatug rezetecan) and ARROS-1's “TKI-naive” cohort of zidesamtinib-treated ROS1-positive patients (not necessarily treatment-naive overall). Aimed at thoracic oncologists, clinical researchers, and medical affairs and market-access teams, the report offers a decision-oriented reference that helps readers rapidly locate where genuinely new information is expected at WCLC 2026, where already-known interim signals are maturing, and where cautious interpretation and independent verification remain essential.